Organisation paid for research Program year 2025 Source: CMS Open Payments

Sarcoma Oncology Research Center

Neither a doctor nor a teaching hospital

Research payments

$3,568,150

255 payments

Through program year 2025, Sarcoma Oncology Research Center is reported as receiving $3,568,150 in research payments, across 255 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $182,645 40
2024 Research $1,004,071 81
2023 Research $1,359,183 64
2022 Research $610,342 27
2021 Research $218,540 14
2020 Research $122,688 21
2019 Research $70,682 8

Breakdown

Who paid Research payments · program years 2019–2025
  1. PTC Therapeutics, Inc. $819,066 25 payments
  2. Aadi Bioscience, Inc. $817,681 13 payments
  3. Trillium Therapeutics USA, LLC $489,904 28 payments
  4. Jazz Pharmaceuticals Inc. $405,115 2 payments
  5. Genentech, Inc. $277,275 26 payments
  6. Epizyme, Inc., $177,759 7 payments
  7. ADC Therapeutics America, Inc. $156,700 108 payments
  8. Karyopharm Therapeutics Inc. $98,009 15 payments
  9. Merck Sharp & Dohme Corporation $71,000 1 payment
  10. Sumitomo Pharma America, Inc. $69,271 8 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2/3 Study to Evaluate the Efficacy and Safety of Unesbulin in Unresectable Or Metastatic, Relapsed Or Refractory Leiomyosarcoma $819,066 25 payments
  2. A Phase III Study of Tti621 in Combination With Doxorubicin in Patients With Unresectable Or Metastatic Highgrade Leiomyosarcoma $479,654 26 payments
  3. Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1TSC2 Genes PRECISION 1 $331,109 1 payment
  4. Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/_TSC2 Genes (PRECISION 1) $326,295 1 payment
  5. IST 12327 - A Phase 1/2 Study of Safety/Efficacy Using LURBINECTEDIN, IPILIMUMAB, and NIVOLUMAB for Advanced Soft Tissue Sarcomas $202,558 1 payment
  6. Linnovate: A Phase 1/2 Study of Safety/Efficacy Using Lurbinectedin, Combined With Ipilimumab, and Nivolumab for Advanced Soft Tissue Sarcomas $202,558 1 payment
  7. Startrk 2 RXDX 101 02 $188,556 20 payments
  8. A Phase1b/3 Global, Randomized, Double-Blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin As Frontline Therapy for Advanced Epithelioid Sarcoma $174,361 6 payments
  9. Adct-601-102 $88,939 45 payments
  10. Mytactic Targeting Actionable Mutation Study in Cancer US Piia Multicenter Nonrandomized Open LBL $80,819 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record